Could the CSL (ASX:CSL) share price get back on track in 2021?

The CSL Limited (ASX: CSL) share price has gone nowhere since March 2020. Citi thinks it could get back on track with the vaccine rollout.

The CSL Limited (ASX: CSL) share price has underperformed the market since the initial COVID-19 sell-off in March 2020. After such a prolonged period of underperformance, Citi thinks the CSL share price could get back on track. 

Strong earnings but plasma collections weigh on CSL share price 

CSL announced a strong half-year report for the six months ended 31 December with group revenue up 16.9% on the prior corresponding period to US$5,739 million. A strong uplift in margins drove its 45% surge in net profit after tax to US$1,810 million. 

At face value, the company's results appear very strong and above CSL's historic mid-teens growth. However, the company did acknowledge that the COVID-19 pandemic had tempered CSL Behring's performance whilst boosting the performance of Seqirus. 

Plasma collections are an essential raw material used in the production of many of the company's therapies. Plasma collection centres and manufacturing facilities are classified as an essential service and remained operational during the pandemic. Despite being open, the company noted in its half-year results that "our plasma collections have been adversely affected during the pandemic". The company reported that collections volumes in December 2020 were ~80% of December 2019 volumes. 

The company has taken several initiatives to improve plasma collections. This includes enhanced targeted marketing initiatives to increase collections, roll out of COVID-19 vaccine to increase social mobility and targeting an additional 12 new centres to be opened in 1H21. 

Citi sees upside to the CSL share price

Citi believes that the current decline in plasma collections is likely to stabilise after the US's COVID vaccine rollout. 

The US has also experienced a significant decline in new daily COVID cases. Its new daily cases surged from an average of 50,000 cases per day in October 2020 to a peak of more than 300,000 cases in January 2021. As of 8 March, the US reported 98,000 cases with a 7-day average of 64,700. 

Citi left its CSL share price target unchanged at $310 with the assumption that plasma donations are back to normal by July 2020. CSL noted that as plasma volumes recover, the cost per litre of plasma reduces, leading to better margins. 

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Happy wife holding her hands on her husband's shoulders while both look at a laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man stands in front of a chart with an arrow going down and slaps his forehead in frustration.
ASX Share Market News

ASX 200 mining shares smashed in major market sell-off

The ASX 200 fell 5.39% amid a mining sell-off, with BHP shares tumbling almost 13% last week.

Read more »

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »